Skip to main content

Treatment Clinical Trials for Breast Cancer Using Trastuzumab

Review the clinical trials testing treatment methods for breast cancer that use trastuzumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 26

ShortStop-HER2: 12 months vs. 6 months of HER2-targeted Medications for People with HER2+ Breast Cancer who Had a Pathologic Complete Response after Chemotherapy Plus Trastuzumab
Status: Active
Location: 211 locations
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Status: Active
Location: 41 locations
Trastuzumab Emtansine Followed by Trastuzumab versus Paclitaxel in Combination with Trastuzumab for the Treatment of HER2-Positive Stage I Breast Cancer, ATEMPT 2.0 Trial
Status: Active
Location: 32 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 33 locations
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Status: Active
Location: 28 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery
Status: Active
Location: 15 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Status: Active
Location: 12 locations
A Study of Surgery and Radiotherapy in People with Oligometastatic HER2 Positive Breast Cancer, ARCHER Trial
Status: Active
Location: 7 locations
Sacituzumab Govitecan and Trastuzumab for the Treatment of HER2+ Metastatic Breast Cancer after Progression on Enhertu, SATEEN Trial
Status: Active
Location: 6 locations
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Status: Active
Location: 5 locations
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 5 locations
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Status: Active
Location: 6 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 4 locations
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Status: Active
Location: 5 locations
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: Active
Location: 3 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
Early Clinical Response Correlation to Pathologic Outcome for Treatment in Patients with Invasive Breast Cancer Undergoing Chemotherapy Before Surgery
Status: Active
Location: 2 locations
Radiation Therapy Followed by Trastuzumab and Pertuzumab for the Treatment of HER2 Positive Breast Cancer that has Spread to the Leptomeninges
Status: Active
Location: 2 locations
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Status: Temporarily Closed to Accrual
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California